NEW YORK (GenomeWeb) – Two insurers have notified healthcare providers in their networks to discontinue using Myriad Genetics for BRCA testing.

In notes sent this week, Horizon Blue Cross Blue Shield of New Jersey and Amerigroup separately advised in-network providers to use only in-network laboratories for BRCA testing, a move that some investment analysts said could negatively impact Myriad.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.